What it's for (Indications)
- Nefopam, marketed under various brand names such as INZA, is a centrally acting non-opioid analgesic primarily indicated for the symptomatic relief of acute and chronic pain.
- Its therapeutic applications encompass a broad spectrum of painful conditions, including post-operative pain, musculoskeletal pain, traumatic pain, dental pain, and certain types of neuropathic pain.
- It is often employed when conventional non-steroidal anti-inflammatory drugs (NSAIDs) are insufficient or contraindicated, and when an opioid-sparing effect is desired, providing a distinct alternative in pain management regimens.
- This drug should be used as prescribed by a qualified healthcare professional, following a thorough assessment of the patient's pain profile and overall health status.
- Its efficacy in managing moderate to severe pain has been demonstrated in various clinical settings, positioning it as a valuable option in multidisciplinary pain management strategies.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of nefopam must be individualized based on the patient's condition, pain severity, and response to treatment, always under strict medical supervision. For oral administration, the typical adult dosage is 30 to 60 mg taken three times daily, with meals, but not exceeding a total daily dose of 180 mg to minimize adverse effects. For intravenous (IV) or intramuscular (IM) administration in adults, a common starting dose is 20 mg, administered slowly over 3-5 minutes for IV, which may be repeated every 4 to 6 hours as needed, up to a maximum daily dose of 120 mg. Dosage adjustments may be necessary in patients with impaired renal or hepatic function, or in elderly individuals, to mitigate the risk of drug accumulation and associated adverse events. Pediatric use is generally not recommended, and careful titration is advised for all patients. |
Safety & Warnings
Common Side Effects
- Nefopam can induce a range of side effects, varying in severity and frequency among individuals.
- Common adverse reactions include nausea, dizziness, dry mouth, sweating (diaphoresis), and tachycardia.
- Other frequently reported effects involve lightheadedness, nervousness, and insomnia, which can impact daily activities.
- More serious, albeit less common, side effects necessitate immediate medical attention and include central nervous system disturbances such as seizures (particularly at higher doses or in predisposed individuals), confusion, hallucinations, and agitation.
- Cardiovascular effects like hypertension and arrhythmias, as well as urinary retention (especially in men with prostatic hypertrophy) and various allergic reactions, have also been reported.
- Patients experiencing severe, persistent, or unusual side effects should consult their healthcare provider promptly for evaluation and management.
Serious Warnings
- Black Box Warning: Serious Warnings: Potential for Seizures, Cardiovascular Instability, and Central Nervous System Effects While nefopam does not carry an FDA-mandated Black Box Warning as it is not currently FDA-approved in the United States, healthcare professionals and patients should be acutely aware of several significant safety concerns that necessitate careful consideration and stringent monitoring during its use. Nefopam has a documented potential to lower the seizure threshold, posing a substantial risk for patients with a history of epilepsy or other convulsive disorders. Therefore, its use in such vulnerable populations is absolutely contraindicated, and extreme caution is warranted in any patient with predisposing factors for seizures. Furthermore, nefopam can induce significant cardiovascular effects, including dose-dependent tachycardia, palpitations, and hypertension. Patients with pre-existing cardiovascular conditions, including recent acute myocardial infarction, severe coronary artery disease, or uncontrolled arrhythmias, are at heightened risk, and the drug is generally contraindicated in these settings. Central nervous system adverse effects, such as confusion, hallucinations, agitation, and disorientation, have been reported, particularly with higher doses or in susceptible individuals, which can impair cognitive function and coordination, increasing the risk of falls or accidents. Close and continuous monitoring for these serious adverse reactions is crucial, and immediate discontinuation may be necessary if they occur. Due to its potential for severe and potentially life-threatening drug interactions, concomitant use with monoamine oxidase inhibitors (MAOIs) is strictly prohibited. Clinicians must conduct a thorough patient assessment before initiating nefopam therapy, weigh the benefits against these serious risks, and educate patients on recognizing and reporting these critical adverse effects.
- Nefopam should be used with extreme caution in patients with a history of seizures or epilepsy, as it is known to significantly lower the seizure threshold, thereby increasing the risk of convulsive episodes.
- Therefore, its use is generally contraindicated in such populations.
- Caution is also profoundly advised in patients with cardiovascular disease, including those with a history of arrhythmias, uncontrolled hypertension, or acute myocardial infarction, due to the potential for dose-dependent tachycardia and elevated blood pressure.
- Patients with angle-closure glaucoma or prostatic hypertrophy are at an increased risk of urinary retention and ocular pressure elevation due to the drug's anticholinergic properties and should be closely monitored.
- Hepatic and renal impairment can lead to drug accumulation and heightened toxicity, necessitating dose adjustments or even contraindication in severe cases.
- This medication has anticholinergic properties, contributing to side effects like dry mouth and urinary retention.
- Concomitant use with other centrally acting drugs, particularly monoamine oxidase inhibitors (MAOIs), is strictly contraindicated due to potential for severe, life-threatening drug interactions.
How it Works (Mechanism of Action)
Nefopam exerts its analgesic effects through a unique mechanism that fundamentally distinguishes it from both opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Its primary mode of action involves the inhibition of the reuptake of three key monoamine neurotransmitters: norepinephrine, serotonin, and to a lesser extent, dopamine, within the central nervous system. This inhibition leads to increased concentrations of these neurotransmitters in the synaptic clefts, particularly in descending pain pathways originating from the brainstem, which subsequently modulates and attenuates pain perception. Additionally, nefopam possesses weak anticholinergic and local anesthetic properties, although these are generally considered secondary to its main monoamine reuptake inhibitory action in contributing to its overall analgesic profile. Critically, it does not bind to opioid receptors, nor does it inhibit prostaglandin synthesis, thereby offering a distinct pharmacological approach to pain management.